Xeris Pharmaceuticals | XERS - Sales Revenues


Xeris Pharmaceuticals reported $83.13M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Celltrion KRW 1.15T 180B Mar/2026
Cspc Pharmaceutical CNY 6.11B 502.75M Dec/2025
Deva Holding AS TRY 2.32B 418.58M Sep/2023
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 26.04B 1.11B Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Kangmei Pharma CNY 1.37B 101.16M Sep/2025
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Laboratorios Farma EUR 448.66M 67.82M Dec/2023
Medical Developments International AUD 21.57M 12.04M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neuren Pharmaceuticals AUD 42.24M 28.1M Dec/2025
Organigram Holdings CAD 63.54M 16.52M Dec/2025
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Pharma Mar EUR 42.9M 47.3M Mar/2026
Qiagen NV USD 419.22M 38.16M Mar/2026
Sartorius EUR 899.1M 28.5M Mar/2026
Sino Biopharmaceutical CNY 14.26B 3.31B Dec/2025
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
Tilray USD 217.51M 74.75M Dec/2025
Zealand Pharma A/S 68.91M 19.35M Dec/2025
Zhangzhou Pientzehuang Pharmaceutical CNY 2.72B 837.63M Mar/2026